𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma

✍ Scribed by Geertsen, P F; Gore, M E; Negrier, S; Tourani, J M; von der Maase, H

Book ID
109998008
Publisher
Nature Publishing Group
Year
2004
Tongue
English
Weight
138 KB
Volume
90
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase II trial of intravenous gemcitab
A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-Ξ± in patients with metastatic renal cell carcinoma
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH

Phase II trial of 5-fluorouracil, interf
Phase II trial of 5-fluorouracil, interferon-Ξ± and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
✍ Julie A. Ellerhorst; Avishay Sella; Robert J. Amato; Shi-Ming Tu; Randall E. Mil πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 90 KB πŸ‘ 1 views

## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d